Templeman Thomas 4
4 · Nuvation Bio Inc. · Filed Feb 12, 2021
Insider Transaction Report
Form 4
Templeman Thomas
SVP, Pharmaceutical Ops
Transactions
- Award
Stock Option (Right to Buy)
2021-02-10+398,935→ 398,935 totalExercise: $4.60Exp: 2030-10-04→ Class A Common Stock (398,935 underlying) - Award
Stock Option (Right to Buy)
2021-02-10+398,935→ 398,935 totalExercise: $1.74Exp: 2030-01-21→ Class A Common Stock (398,935 underlying)
Footnotes (4)
- [F1]Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer").
- [F2]Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria.
- [F3]Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock.
- [F4]Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years.